AzTrials
AzTrials

Morbid ObesityNCT05428540

Polyphenol Supplementation and Morbid Obesity Parameters

A study testing Polyphenol-rich supplement in people with Morbid Obesity, run by Institut d'Investigació Biomèdica de Bellvitge at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This parallel, double-blind, randomised controlled trial aims to assess the effect of a polyphenol-rich dietary supplement on obesity parameters, in combination with a hypocaloric diet, for adults with morbid obesity, bariatric surgery candidates. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Morbid Obesity
What is being tested?
Polyphenol-rich supplement
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
37 participants
Where
1 siteSpain
Study dates
8 Aug 2022to 16 Jun 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults ≥ 18 years old
  • Presenting morbid obesity defined as BMI ≥ 40 kg/m2
  • Referred to the Endocrinology and Nutrition Unit from Bellvitge University Hospital for a weight loss treatment

Who cannot join

  • History of type I diabetes
  • Endocrine disorders-derived obesity
  • Acute metabolic complications
  • Severe inflammatory process that might affect the inflammatory condition during the 4 weeks before inclusion
  • Cardiovascular event during the 6 months before inclusion
  • History of hepatopathy or alteration of hepatic function
Show all 10Show fewer
  • Pregnant, lactation period or willing to get pregnant in the 12 weeks after inclusion
  • Recent history of neoplasia (< 5 years) except for skin cancer or melanoma
  • Oral or IV line glucocorticoids during 14 consecutive days or more 3 months before inclusion
  • Alcoholism, drug addiction or major psychiatric disorder

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Hospital Universitario de Bellvitge

    L'Hospitalet de Llobregat, Barcelona, 08907

Other trials in Spain

About this study

Official title: Influence of a Polyphenol-rich Supplement on Anthropometric, Biochemical and Inflammatory Parameters in Participants With Morbid Obesity

This parallel, double-blind, randomised controlled trial aims to assess the effect of a polyphenol-rich dietary supplement on obesity parameters, in combination with a hypocaloric diet, for adults with morbid obesity, bariatric surgery candidates.

Participants (n=40) will be randomly assigned to intervention group (IG) or control group (CG). Together with a regular hypocaloric diet (1,200 kcal/d), the IG will be given the supplement and the CG will be given a placebo. Both groups will take three capsules a day (400 mg per capsule, a total of 1,200 mg), distributed in three daily intakes (with meals). After 12 weeks and 3 visits (baseline visit, week 6 and week 12), pre and post intervention data and intervention versus placebo data will be analysed. Anthropometric and health parameters, dietary habits, lifestyle characteristics and physical activity will be assessed, and blood and urine samples will be collected in all three visits. Faecal samples will be collected at baseline and visit 3.

Results will provide evidence on the effects of a combination of polyphenols on several well-established obesity parameters and will unravel possible underlying mechanisms by metabolomic analyses and microbiota diversity.

Read the detailed description

The main objective of this study is to assess the effect of a polyphenol-rich dietary supplement, along with a hypocaloric diet, on obesity parameters in participants with morbid obesity. Anthropometric, biochemical and inflammatory parameters, as well as different metabolic pathways and microbiota diversity will be assessed.

The estimated number of participants to include is 40. They will be patients with morbid obesity, referred to the Endocrinology and Nutrition Unit from Bellvitge University Hospital for a weight loss treatment, in many cases prior to a bariatric surgery. To estimate the sample size the following assumptions were made: same number of participants in each group; 10% variation in anthropometric and laboratory measurements; trial power of 0.85 and alfa error of 5%; estimated losses to follow-up: 15%.

The main component of the intervention is a polyphenol-rich dietary supplement administrated for 12 weeks. Lifestyle, dietary, physical activity data and blood and urine samples will be collected in three visits (baseline, week 6 and week 12); faecal samples will be collected in visits baseline and week 12. All participants will follow a hypocaloric diet and will be randomly assigned to either intervention group (IG) or control group (CG) after recruitment, following a simple randomisation procedure. The IG will take the supplement (3 capsules/day), whereas the CG will take a placebo (3 capsules/day).

This trial will be carried out following the ethical guidelines of the Declaration of Helsinki, the Principles of the Good Clinical Practice, under the existing legislation. Data collected will be kept strictly confidential. Any participant will have the right to access, rectification, cancellation and opposition over such data in accordance with the Organic Law 15/1999, Personal Data Protection. All information will be stored in a Data Collection Notebook, from which the database will be created.

All participants will be provided with an information sheet and will have to sign a consent form before the beginning of this trial. Any participant will be allowed to abandon the study for any reason: if requested; if the suspension is in the medical interest; if an incidence is presented as a consequence of the intervention, inacceptable or representing a threat to the participants' health; if the participant presents any breakthrough disease or other condition that, according to the principal investigator (PI), are relevant to suspend the intervention.

Data on medical history, lifestyle and sociodemographic characteristics will be collected through participants' clinical records and interviews at baseline. The standard hypocaloric diet (1200 kcal) that participants will have to follow for the entire 12 weeks of the study will be explained to each participant on the first visit.

On each visit participants will provide a 3-day food record, completed the three days preceding such visits. Qualified staff will collect data on dietary habits through a 24-hours dietary recall and will take anthropometric measurements, including height, weight, hip and waist circumference, body composition using an ergonomic measuring tape and a bioimpedance scan. Dietary and anthropometric assessment will be performed following the standard procedures from the Dietetic and Clinical Nutrition Unit from Bellvitge University Hospital.

Programari de Càlcul Nutricional Pro 1.0 Software, developed by University of Barcelona, will be used to assess dietary and nutritional intake. It includes a high-quality contrasted database which makes possible to calculate and analyse nutritional intake and body composition.

Phenol-Explorer database will be used to assess polyphenol intake. It is the first comprehensive database on polyphenol content in foods which takes into account food processing and cooking and contains more than 35,000 content values for 500 different polyphenols over 400 foods.

On each visit qualified staff will collect data on physical activity through a shortened version in Spanish of the Minnesota Leisure Time Physical Activity Questionnaire and will measure blood pressure through a semi-automated oscillometer.

Prior to each visit participants will need to fast for 12 hours as they will have blood samples taken. On each visit, 20ml of blood will be extracted from the antecubital vein and will be centrifuged and stored at -80ºC until used. Biochemical analyses will be performed by the Bellvitge University Hospital analysis laboratory. Blood tests will include rutinary hematology and biochemistry, and inflammatory parameters.

On each visit participants will have to 24-hour urine samples. Three aliquots (2 ml each) will be stored at -80ºC in the ultra-freezers of the Unit of Nutrition and Cancer, Institut d'Investigació Biomedica de Bellvitge (IDIBELL) (Barcelona, Spain). One aliquot will be used to measure cortisol in the clinical laboratory of the Bellvitge University Hospital. Another aliquot will be used to perform a metabolomic analysis by the Nutritional Biomarkers and Metabolomics group from the University of Barcelona. About ≈ 500 metabolites (e.g., polyphenols and microbiota metabolites, organic acids, energetic and protein metabolism compounds) will be quantified using ultra-high performance liquid chromatography coupled to tandem mass spectrometry. This will allow us to monitor metabolite alterations derived from the polyphenol-rich supplement and associate these changes with improvements in clinical and biochemical outcome measurements.

Participants will bring a faecal sample in the first and third visit. These samples will be analysed in future microbiota studies. They will be kept stored at -80ºC in the ultra-freezers of the Unit of Nutrition and Cancer, IDIBELL.

Statistical analysis plan: intention-to-treat and per-protocol analyses will be performed. The main variable to assess is body weight and body composition. Secondary variables include biochemical and inflammatory parameters, urine metabolites and microbiota. Pre and post data, and IG versus CG results will be compared using Student t-test for paired and for independent samples, respectively.

Conditions
Morbid Obesity
Being tested
Polyphenol-rich supplement, Placebo
Medical subject headings
Obesity, Morbid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Polyphenol-rich supplementDietary supplement

    Polyphenol-rich capsules containing 1,200 mg of a combination of plant extracts rich in polyphenols. Frequency: 3 capsules a day. Duration: 12 weeks.

  • PlaceboOther

    Placebo

Study groups in NCT05428540
Study groupRoleWhat they receive
Intervention groupExperimentalPolyphenol-rich dietary supplement (3 capsules/day) + hypocaloric diet (1,200 kcal/day)
Receives: Dietary Supplement: Polyphenol-rich supplement
Control groupPlacebo comparatorPlacebo (3 capsules/day) + hypocaloric diet (1,200 kcal/day)
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Body weight

    Unit: Kilograms Measured with:bioimpedance scan

    Measured: Visit 1 (baseline)

  2. Body weight

    Unit: Kilograms Measured with:bioimpedance scan

    Measured: Visit 2 (week 6)

  3. Body weight

    Unit: Kilograms Measured with:bioimpedance scan

    Measured: Visit 3 (week 12)

Secondary outcomes (90)
  1. Systolic blood pressure

    Unit: mmHg Measured with: oscillometer

    Measured: Visit 1 (baseline)

  2. Diastolic blood pressure

    Unit: mmHg Measured with: oscillometer

    Measured: Visit 1 (baseline)

  3. Systolic blood pressure

    Unit: mmHg Measured with: oscillometer

    Measured: Visit 2 (week 6)

  4. Diastolic blood pressure

    Unit: mmHg Measured with: oscillometer

    Measured: Visit 2 (week 6)

  5. Systolic blood pressure

    Unit: mmHg Measured with: oscillometer

    Measured: Visit 3 (week 12)

  6. Diastolic blood pressure

    Unit: mmHg Measured with: oscillometer

    Measured: Visit 3 (week 12)

  7. Dietary intake

    24-h dietary recall

    Measured: Visit 1 (baseline)

  8. Dietary intake

    24-h dietary recall

    Measured: Visit 2 (week 6)

  9. Dietary intake

    24-h dietary recall

    Measured: Visit 3 (week 12)

  10. Physical activity level

    Formula: metabolic energy turnover (MET) according to Ainsworth proposal (Compendium of Physical Activities, 2011) Unit: METS-minute/14 days

    Scale:

    <1250: sedentary 1250 to 2999: moderately active 3000-4999: active >=5000: very active

    Measured: Visit 1 (baseline)

  11. Physical activity level

    Formula: metabolic energy turnover (MET) according to Ainsworth proposal (Compendium of Physical Activities, 2011) Unit: METS-minute/14 days

    Scale:

    <1250: sedentary 1250 to 2999: moderately active 3000-4999: active >=5000: very active

    Measured: Visit 2 (week 6)

  12. Physical activity level

    Formula: metabolic energy turnover (MET) according to Ainsworth proposal (Compendium of Physical Activities, 2011) Unit: METS-minute/14 days

    Scale:

    <1250: sedentary 1250 to 2999: moderately active 3000-4999: active >=5000: very active

    Measured: Visit 3 (week 12)

  13. Alanine aminotransferase

    Measured through plasma concentrations:

    Unit: units/litre

    Measured: Visit 1 (baseline)

  14. Alanine aminotransferase

    Measured through plasma concentrations:

    Unit: units/litre

    Measured: Visit 2 (week 6)

  15. Alanine aminotransferase

    Measured through plasma concentrations:

    Unit: units/litre

    Measured: Visit 3 (week 12)

  16. Aspartate aminotransferase

    Measured through plasma concentrations Units: units/litre

    Measured: Visit 1 (baseline)

  17. Aspartate aminotransferase

    Measured through plasma concentrations Units: units/litre

    Measured: Visit 2 (week 6)

  18. Aspartate aminotransferase

    Measured through plasma concentrations Units: units/litre

    Measured: Visit 3 (week 12)

  19. Bilirrubin

    Measured through plasma concentrations Unit: mg/dl

    Measured: Visit 1 (baseline)

  20. Bilirrubin

    Measured through plasma concentrations Unit: mg/dl

    Measured: Visit 2 (week 6)

  21. Bilirrubin

    Measured through plasma concentrations Unit: mg/dl

    Measured: Visit 3 (week 12)

  22. Thyroid-stimulating hormone (TSH)

    Measured through plasma concentrations (mU/litre)

    Measured: Visit 1 (baseline)

  23. Thyroid-stimulating hormone (TSH)

    Measured through plasma concentrations (mU/litre)

    Measured: Visit 2 (week 6)

  24. Thyroid-stimulating hormone (TSH)

    Measured through plasma concentrations (mU/litre)

    Measured: Visit 3 (week 12)

  25. Thyroxine

    Measured through plasma concentrations (ng/dl)

    Measured: Visit 1 (baseline)

  26. Thyroxine

    Measured through plasma concentrations (ng/dl)

    Measured: Visit 2 (week 6)

  27. Thyroxine

    Measured through plasma concentrations (ng/dl)

    Measured: Visit 3 (week 12)

  28. Creatinin

    Measured through plasma concentrations (mg/dl)

    Measured: Visit 1 (baseline)

  29. Creatinin

    Measured through plasma concentrations (mg/dl)

    Measured: Visit 2 (week 6)

  30. Creatinin

    Measured through plasma concentrations (mg/dl)

    Measured: Visit 3 (week 12)

  31. Urea

    Measured through plasma concentrations (mg/dl)

    Measured: Visit 1 (baseline)

  32. Urea

    Measured through plasma concentrations (mg/dl)

    Measured: Visit 2 (week 6)

  33. Urea

    Measured through plasma concentrations (mg/dl)

    Measured: Visit 3 (week 12)

  34. Erithrocytes

    Plasma concentrations (cel/mcl)

    Measured: Visit 1 (baseline)

  35. Erithrocytes

    Plasma concentrations (cel/mcl)

    Measured: Visit 2 (week 6)

  36. Erithrocytes

    Plasma concentrations (cel/mcl)

    Measured: Visit 3 (week 12)

  37. Hemoglobin

    Plasma concentrations (g/dl)

    Measured: Visit 1 (baseline)

  38. Hemoglobin

    Plasma concentrations (g/dl)

    Measured: Visit 2 (week 6)

  39. Hemoglobin

    Plasma concentrations (g/dl)

    Measured: Visit 3 (week 12)

  40. Leucocytes

    Plasma concentrations (cel/mcl)

    Measured: Visit 1 (baseline)

  41. Leucocytes

    Plasma concentrations (cel/mcl)

    Measured: Visit 2 (week 6)

  42. Leucocytes

    Plasma concentrations (cel/mcl)

    Measured: Visit 3 (week 12)

  43. Total cholesterol

    Plasma concentrations (mg/dl)

    Measured: Visit 1 (baseline)

  44. Total cholesterol

    Plasma concentrations (mg/dl)

    Measured: Visit 2 (week 6)

  45. Total cholesterol

    Plasma concentrations (mg/dl)

    Measured: Visit 3 (week 12)

  46. LDL (low-density lipoprotein)-cholesterol

    Plasma concentrations (mg/dl)

    Measured: Visit 1 (baseline)

  47. LDL (low-density lipoprotein)-cholesterol

    Plasma concentrations (mg/dl)

    Measured: Visit 2 (week 6)

  48. LDL (low-density lipoprotein)-cholesterol

    Plasma concentrations (mg/dl)

    Measured: Visit 3 (week 12)

  49. HDL (high-density lipoprotein)-cholesterol

    Plasma concentrations (mg/dl)

    Measured: Visit 1 (baseline)

  50. HDL (high-density lipoprotein)-cholesterol

    Plasma concentrations (mg/dl)

    Measured: Visit 2 (week 6)

  51. HDL (high-density lipoprotein)-cholesterol

    Plasma concentrations (mg/dl)

    Measured: Visit 3 (week 12)

  52. Triglycerides

    Plasma concentrations (mg/dl)

    Measured: Visit 1 (baseline)

  53. Triglycerides

    Plasma concentrations (mg/dl)

    Measured: Visit 2 (week 6)

  54. Triglycerides

    Plasma concentrations (mg/dl)

    Measured: Visit 3 (week 12)

  55. Glucose

    Plasma concentrations (mg/dl)

    Measured: Visit 1 (baseline)

  56. Glucose

    Plasma concentrations (mg/dl)

    Measured: Visit 2 (week 6)

  57. Glucose

    Plasma concentrations (mg/dl)

    Measured: Visit 3 (week 12)

  58. Glycosylated hemoglobin

    Measured through plasma concentrations Unit: %

    Measured: Visit 1 (baseline)

  59. Glycosylated hemoglobin

    Measured through plasma concentrations Unit: %

    Measured: Visit 2 (week 6)

  60. Glycosylated hemoglobin

    Measured through plasma concentrations Unit: %

    Measured: Visit 3 (week 12)

  61. Insulin

    Measured through plasma concentrations Unit/ml

    Measured: Visit 1 (baseline)

  62. Insulin

    Measured through plasma concentrations Unit/ml

    Measured: Visit 2 (week 6)

  63. Insulin

    Measured through plasma concentrations Unit/ml

    Measured: Visit 3 (week 12)

  64. TNF-alpha receptor I

    Measured through plasma levels (pg/ml)

    Measured: Visit 1 (baseline)

  65. TNF-alpha receptor I

    Measured through plasma levels (pg/ml)

    Measured: Visit 2 (week 6)

  66. TNF-alpha receptor I

    Measured through plasma levels (pg/ml)

    Measured: Visit 3 (week 12)

  67. TNF-alpha receptor II

    Measured through plasma levels (pg/ml)

    Measured: Visit 1 (baseline)

  68. TNF-alpha receptor II

    Measured through plasma levels (pg/ml)

    Measured: Visit 2 (week 6)

  69. TNF-alpha receptor II

    Measured through plasma levels (pg/ml)

    Measured: Visit 3 (week 12)

  70. Interleukin-6

    Measured through plasma levels (pg/ml)

    Measured: Visit 1 (baseline)

  71. Interleukin-6

    Measured through plasma levels (pg/ml)

    Measured: Visit 2 (week 6)

  72. Interleukin-6

    Measured through plasma levels (pg/ml)

    Measured: Visit 3 (week 12)

  73. Adiponectin

    Measured through plasma levels (ug/ml)

    Measured: Visit 1 (baseline)

  74. Adiponectin

    Measured through plasma levels (ug/ml)

    Measured: Visit 2 (week 6)

  75. Adiponectin

    Measured through plasma levels (ug/ml)

    Measured: Visit 3 (week 12)

  76. high sensitivity c-reactive protein

    Measured through plasma levels (mg/l)

    Measured: Visit 1 (baseline)

  77. high sensitivity c-reactive protein

    Measured through plasma levels (mg/l)

    Measured: Visit 2 (week 6)

  78. high sensitivity c-reactive protein

    Measured through plasma levels (mg/l)

    Measured: Visit 3 (week 12)

  79. Waist circumference

    Unit: centimetres Measured with: ergonomic measuring tape

    Measured: Visit 1 (baseline)

  80. Waist circumference

    Unit: centimetres Measured with: ergonomic measuring tape

    Measured: Visit 2 (week 6)

  81. Waist circumference

    Unit: centimetres Measured with: ergonomic measuring tape

    Measured: Visit 3 (week 12)

  82. Hip circumference

    Unit: centimetres Measured with: ergonomic measuring tape

    Measured: Visit 1 (baseline)

  83. Hip circumference

    Unit: centimetres Measured with: ergonomic measuring tape

    Measured: Visit 2 (week 6)

  84. Hip circumference

    Unit: centimetres Measured with: ergonomic measuring tape

    Measured: Visit 3 (week 12)

  85. Fat mass

    Unit: % Measured with: bioimpedance scan

    Measured: Visit 1 (baseline)

  86. Fat mass

    Unit: % Measured with: bioimpedance scan

    Measured: Visit 2 (week 6)

  87. Fat mass

    Unit: % Measured with: bioimpedance scan

    Measured: Visit 3 (week 12)

  88. Muscle mass

    Unit: % Measured with: bioimpedance scan

    Measured: Visit 1 (baseline)

  89. Muscle mass

    Unit: % Measured with: bioimpedance scan

    Measured: Visit 2 (week 6)

  90. Muscle mass

    Unit: % Measured with: bioimpedance scan

    Measured: Visit 3 (week 12)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jun 2022
  2. Study start8 Aug 2022
  3. Primary completion16 Jun 2023
  4. Study completion16 Jun 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
37 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05428540
Sponsor's protocol ID
Polyphenols and morbid obesity
Status last verified
Aug 2023
First submitted
10 Jun 2022
Last updated
9 Aug 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Sagues-Farreras D, Gil-Lespinard M, Gholamalizadeh M, Bonet C, Guinon-Fort D, Montserrat M, Virgili-Casas N, Zamora-Ros R. Effects of a (poly)phenol-rich supplement on body composition and cardiometabolic health in adults with severe obesity: a randomized controlled trial. Nutr Metab Cardiovasc Dis. 2026 Aug 25:104969. doi: 10.1016/j.numecd.2026.104969. Online ahead of print.

    PubMed 42760234

Questions about this trial

What is this clinical trial studying?

A study testing Polyphenol-rich supplement in people with Morbid Obesity, run by Institut d'Investigació Biomèdica de Bellvitge at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Body weight (time frame: Visit 1 (baseline)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05428540, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in